These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 25045284)
21. Patients' Preferences for Androgen Deprivation Therapy in the Treatment of Intermediate-Risk Prostate Cancer. De B; Lowenstein LM; Corrigan KL; Andring LM; Kuban DA; Cantor SB; Volk RJ; Hoffman KE MDM Policy Pract; 2022; 7(2):23814683221137752. PubMed ID: 36405544 [TBL] [Abstract][Full Text] [Related]
22. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer. Higano CS Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627 [TBL] [Abstract][Full Text] [Related]
23. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Daniell HW Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461 [TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation therapy: indications, methods of utilization, side effects and their management. Magee DE; Singal RK Can J Urol; 2020 Feb; 27(27 Suppl 1):11-16. PubMed ID: 32101695 [TBL] [Abstract][Full Text] [Related]
25. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Grossmann M; Zajac JD Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052 [TBL] [Abstract][Full Text] [Related]
26. 'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer. Lomax AJ; Parente P; Gilfillan C; Livingston PM; Davis ID; Pezaro C Intern Med J; 2016 Feb; 46(2):141-8. PubMed ID: 25732203 [TBL] [Abstract][Full Text] [Related]
27. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. Gomella LG BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166 [TBL] [Abstract][Full Text] [Related]
28. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285 [TBL] [Abstract][Full Text] [Related]
29. Indications and Complications of Androgen Deprivation Therapy. Fankhauser CD; Wettstein MS; Reinhardt M; Gessendorfer A; Mostafid H; Hermanns T Semin Oncol Nurs; 2020 Aug; 36(4):151042. PubMed ID: 32773255 [TBL] [Abstract][Full Text] [Related]
30. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. Mottet N; Prayer-Galetti T; Hammerer P; Kattan MW; Tunn U BJU Int; 2006 Jul; 98(1):20-7. PubMed ID: 16566812 [TBL] [Abstract][Full Text] [Related]
31. Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician. Siebert AL; Lapping-Carr L; Morgans AK Eur Urol Focus; 2020 Nov; 6(6):1170-1179. PubMed ID: 32690473 [TBL] [Abstract][Full Text] [Related]
32. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492 [TBL] [Abstract][Full Text] [Related]
33. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? Klotz L; Toren P Curr Oncol; 2012 Dec; 19(Suppl 3):S13-21. PubMed ID: 23355789 [TBL] [Abstract][Full Text] [Related]